A Review of TITAN Trial for Prostate Cancer
Main Article Content
Abstract
The TITAN trial, a phase III, randomized, double-blind, placebo-controlled study, evaluated the efficacy and safety of apalutamide in combination with androgen deprivation therapy (ADT) for patients with metastatic castration-sensitive prostate cancer (mCSPC). The trial included 1,052 patients randomized to receive apalutamide or placebo plus ADT, with primary endpoints of overall survival (OS) and radiographic progression-free survival (rPFS). Results demonstrated that apalutamide significantly improved OS and rPFS, with a 35% reduction in the risk of death (HR, 0.65; 95% CI, 0.53–0.79; P<0.001) at a median follow-up of 44 months. Health-related quality of life (HRQOL) was maintained during treatment. Adverse events more common in the apalutamide group included rash (27.1%), hypothyroidism, and ischemic heart disease, but these were manageable.
The TITAN trial established apalutamide plus ADT as an effective and well-tolerated treatment option for mCSPC, offering significant survival benefits while preserving quality of life.
Article Details
This work is licensed under a Creative Commons Attribution 4.0 International License.
References
I. Prostate Cancer, Version 4.2023, NCCN Clinical Practice Guidelines in Oncology. Schaeffer EM, Srinivas S, Adra N, et al. Journal of the National Comprehensive Cancer Network: JNCCN. 2023;21(10):1067-1096. doi:10.6004/jnccn.2023.0050.
II. Apalutamide in Patients with Metastatic Castration-Sensitive Prostate Cancer: Final Survival Analysis of the Randomized, Double-Blind, Phase III TITAN Study. Chi KN, Chowdhury S, Bjartell A, et al. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology. 2021;39(20):2294-2303. doi:10.1200/JCO.20.03488.
III. Health-Related Quality of Life After Apalutamide Treatment in Patients With Metastatic Castration-Sensitive Prostate Cancer (TITAN): A Randomised, Placebo-Controlled, Phase 3 Study. Agarwal N, McQuarrie K, Bjartell A, et al. The Lancet. Oncology. 2019;20(11):1518-1530. doi:10.1016/S1470-2045(19)30620-5.
IV. Updates to Advanced Prostate Cancer: AUA/SUO Guideline (2023). Lowrance W, Dreicer R, Jarrard DF, et al. The Journal of Urology. 2023;209(6):1082-1090. doi:10.1097/JU.0000000000003452.
V. Castration-Resistant Prostate Cancer: AUA Guideline Amendment 2018. Lowrance WT, Murad MH, Oh WK, et al. The Journal of Urology. 2018;200(6):1264-1272. doi:10.1016/j.juro.2018.07.090.